JOURNEY OF EVOLUTION

FROM FY1989 TO FY2010

    FY1989-FY1996   FY1997-FY2003   FY2004-FY2010
Domestic Formulations
  • Commissioned manufacturing facilities at Pithampur
  • Acquired Roche India operations
  • In-licensing agreement with FHL Roche, Basel
  • Acquired Bulk Drug Division of Sumitra Pharmaceuticals including Digwal facility
  • Closed high cost plants in Mumbai & Thane. Transferred production to cost effective plants at Pithampur & Mahad
  • JV with Ambalal Sarabhai Enterprises
  • Acquired Rhone Poulenc India
  • Global Bulk Drugs and Fine Chemicals merged with PEL
  • Acquired Boehringer Mannheim
  • Triple merger of the Piramal Healthcare, Boehringer Mannheim and Nicholoas Piramal
  • Acquired pharma business of ICI India Limited
  • Closed four acquired plants, consolidated their manufacturing at Pithampur and integrated distribution to derive significant cost synergies
  • Acquired balance 50% in JV with Ambalal Sarabhai Enterprises
  • Created the largest field force in India
  • Invested in a new state of the art formulations manufacturing facility at Baddi
  • Launched 32 new products/extensions
  • Became 3rd largest player in India with a market share of 4.4%
Pharma Solutions  
  • Upgraded and expanded capacity at Pithampur facility to cater to the export markets
  • Upgraded and expanded capacity at Digwal facility to cater to the export markets and comply with US FDA standards
  • Commissioned manufacturing facility at Ennore, including laboratories for early phase API development
  • Acquired Avecia Pharmaceuticals (UK) - gave access to :
  • Grangemouth (Scotland) – for ADCs
  • Torcan (Canada) - For APIs
  • Huddersfield (UK) - For APIs
  • Shutdown Huddersfield (UK) and shifted manufacturing to Digwal
  • Acquired Morpeth (UK) facility from Pfizer Inc.
  • Commissioned an early phase formulation development facility at Ahmedabad and introduced Clinical Trial Packaging services at Morpeth
  • Pfizer renewed manufacturing contract at Morpeth facility for an indefinite period
Critical Care  
  • Acquisition of ICI India Limited gave entry in Inhalation Anaesthetics: Halothane
  • Acquired Inhalation Anaesthetics business of Rhodia Organique, UK - Distribution network across 58 countries and manufacturing technology for Halothane & Isoflurane and Bethlehem manufacturing site
  • Acquisition of brand Haemaccel from Plasmaselect, Germany
  • Acquired Minrad Inc., US - Gave access to Sevoflurane & Desflurane
  • Acquired Rxelite Inc., US - Gave direct presence in the region
  • Sevoflurane US market share increased to 18%
Consumer Products
  • Entered JV with Allergan - Ophthalmic product
  • JV with Reckitt from FY1998 to FY2002
  • JV with Boots Plc in FY1999
  • Acquired balance 51% in JV with Boots in FY2007 and independently started OTC business
  • Product portfolio included Saridon, Lacto and Polycrol
  • Launched Itchmosol, Jungle Magic
  • Acquired i-pill
  • Towns Presence - 221 towns
  • Retail outlets - 1,00,000
  • Chemist outlets - 35,000

Note : The above table is not covering evolution of Diagnostics Pathlabs, Diagnostics Equipments and India NCE businesses.